Brief: Agile Therapeutics Provides Updates On 2022 Twirla Performance And 2023 Commercial Plan
09/01/2023 13:40
Jan 9 (Reuters) - Agile Therapeutics Inc AGRX.O :
* AGILE THERAPEUTICS PROVIDES UPDATES ON 2022 TWIRLA
PERFORMANCE
AND 2023 COMMERCIAL PLAN
* AGILE THERAPEUTICS INC SEES FY REVENUE $25.0 MILLION TO
$30.0
MILLION
* AGILE THERAPEUTICS INC - Q4 2022 TWIRLA FACTORY SALES
EXPECTED
TO INCREASE APPROXIMATELY 30% FROM Q3 2022
* AGILE THERAPEUTICS INC - FULL YEAR 2022 FACTORY SALES
EXPECTED
TO INCREASE APPROXIMATELY 232% FROM FULL YEAR 2021
Source text for Eikon: ID:nGNX8WSbv5
Further company coverage: AGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Agile Therapeutics
See all newsBrief: Agile Therapeutics Inc. Announces Definitive Merger Agreement With Insud Pharma, S.L.
Agile Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Agile Therapeutics Announces Delisting From Nasdaq
Agile Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
Brief: Agile Therapeutics Completes Pay-Off Of Debt